Candel Therapeutics, Inc. CADL Deferred Debt Issuance Costs In Accounts Payable And Accrued Expenses
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept cadl:DeferredDebtIssuanceCostsInAccountsPayableAndAccruedExpenses.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s deferred debt issuance costs in accounts payable and accrued expenses.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s deferred debt issuance costs in accounts payable and accrued expenses?
- Candel Therapeutics, Inc. (CADL) reported deferred debt issuance costs in accounts payable and accrued expenses of $299K in Q1 2026.